This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Abiomed Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Mike Minogue

Amministratore delegato

US$12.7m

Compenso totale

Percentuale dello stipendio del CEO	6.2%
Mandato del CEO	18.7yrs
Proprietà del CEO	0.8%
Durata media del management	4.5yrs
Durata media del Consiglio di amministrazione	8.3yrs

Aggiornamenti recenti sulla gestione

Recent updates

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Jan 24

Abiomed: Impella Will Continue To Drive Revenue Growth

Sep 10

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

Jul 13

DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue

Jun 08

Abiomed acquires preCARDIA a company targeting acute heart failure

Jun 01

Boston Scientific’s new clinical trial can impact Abiomed: Raymond James

May 06

Abiomed FQ4 2021 Earnings Preview

Apr 28

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Mike Minogue rispetto agli utili di Abiomed?
Data	Compenso totale	Stipendio	Guadagni aziendali
Sep 30 2022	n/a	n/a	US$267m
Jun 30 2022	n/a	n/a	US$218m
Mar 31 2022	US$13m	US$789k	US$137m
Dec 31 2021	n/a	n/a	US$133m
Sep 30 2021	n/a	n/a	US$149m
Jun 30 2021	n/a	n/a	US$154m
Mar 31 2021	US$15m	US$608k	US$226m
Dec 31 2020	n/a	n/a	US$200m
Sep 30 2020	n/a	n/a	US$208m
Jun 30 2020	n/a	n/a	US$159m
Mar 31 2020	US$17m	US$768k	US$203m
Dec 31 2019	n/a	n/a	US$245m
Sep 30 2019	n/a	n/a	US$221m
Jun 30 2019	n/a	n/a	US$258m
Mar 31 2019	US$19m	US$753k	US$259m
Dec 31 2018	n/a	n/a	US$222m
Sep 30 2018	n/a	n/a	US$190m
Jun 30 2018	n/a	n/a	US$165m
Mar 31 2018	US$10m	US$718k	US$112m
Dec 31 2017	n/a	n/a	US$90m
Sep 30 2017	n/a	n/a	US$92m
Jun 30 2017	n/a	n/a	US$77m
Mar 31 2017	US$12m	US$649k	US$52m
Dec 31 2016	n/a	n/a	US$48m
Sep 30 2016	n/a	n/a	US$43m
Jun 30 2016	n/a	n/a	US$42m
Mar 31 2016	US$19m	US$630k	US$38m

Compensazione vs Mercato: La retribuzione totale di Mike ($USD 12.67M ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 12.86M ).

Compensazione vs guadagni: La retribuzione di Mike è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Mike Minogue (55 yo)

18.7yrs

Mandato

US$12,665,992

Compensazione

Mr. Michael R. Minogue, also known as Mike, served as Director at Medical Device Innovation Consortium, previously served as its chairman until June 2019. He has been Chief Executive Officer and President...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Minogue	Chairman	18.7yrs	US$12.67m	0.77% $ 133.2m
Todd Trapp	Executive VP & CFO	4.7yrs	US$3.04m	0.017% $ 2.9m
Marc Began	Executive VP	4.5yrs	US$2.57m	0.027% $ 4.7m
Andrew Greenfield	Executive VP & Chief Commercial Officer	2.7yrs	US$2.84m	0.045% $ 7.8m
David Weber	Scientific & Technology Advisor	less than a year	US$2.29m	0.30% $ 52.2m
Matthew Plano	Executive Vice President of Global Operations & Integration	no data	Nessun dato	0.017% $ 3.0m
Thorsten Siess	Executive VP & Chief Technology Officer	no data	Nessun dato	Nessun dato
Ingrid Ward	Director of Investor Relations	8.3yrs	Nessun dato	Nessun dato
Sarah Karr	Communications Manager	no data	Nessun dato	Nessun dato
Michael Howley	VP & GM of Global Sales	13.8yrs	US$1.71m	Nessun dato
Karen Mahoney	VP & Chief Human Resources Officer	3.3yrs	Nessun dato	Nessun dato
Charles Simonton	Executive VP & Chief Medical Officer	2.5yrs	Nessun dato	Nessun dato

4.5yrs

Durata media

55yo

Età media

Gestione esperta: Il team dirigenziale di ABMD è considerato esperto (durata media dell'incarico 4.5 anni).

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Michael Minogue	Chairman	18.7yrs	US$12.67m	0.77% $ 133.2m
Martin Sutter	Independent Director	14.6yrs	US$266.80k	0.26% $ 45.2m
Jeannine Rivet	Independent Director	6.8yrs	US$266.80k	0.021% $ 3.5m
Paul Thomas	Independent Director	11.6yrs	US$269.30k	0.013% $ 2.2m
Eric Rose	Independent Director	8.3yrs	US$259.30k	0.032% $ 5.5m
Dorothy Puhy	Independent Lead Director	19.3yrs	US$299.30k	0.032% $ 5.4m
Paula Johnson	Independent Director	1.7yrs	US$499.89k	0.0011% $ 190.8k
Christopher Van Gorder	Independent Director	6.8yrs	US$264.30k	0.015% $ 2.6m
Myron Rolle	Independent Director	1.8yrs	US$259.30k	0.0011% $ 195.9k

8.3yrs

Durata media

67yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di ABMD sono considerati esperti (durata media dell'incarico 8.3 anni).

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2022/12/24 15:35
Prezzo dell'azione a fine giornata	2022/12/21 00:00
Guadagni	2022/09/30
Guadagni annuali	2022/03/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

^* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .

Fonti analitiche

Abiomed, Inc. è coperta da 26 analisti. 3 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Lawrence Neibor	Baird
Jan Wald	Benchmark Company
Michael Gorman	BTIG

This company has been acquired

Abiomed Gestione

Gestione criteri di controllo 4/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold US$1.2m worth of stock

Recent updates

Johnson & Johnson (NYSE:JNJ) completed the acquisition of Abiomed, Inc. (NasdaqGS:ABMD).

Abiomed Announces United States Food and Drug Administration Approves Version of Impella ECP

Abiomed, Inc.(NasdaqGS:ABMD) dropped from FTSE All-World Index (USD)

Abiomed, Inc. Announces First Patients in the World Treated with Impella Rp Flex with Smartassist

Price target increased to US$362

Independent Director notifies of intention to sell stock

Executive VP notifies of intention to sell stock

Independent Director notifies of intention to sell stock

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Johnson & Johnson (NYSE:JNJ) entered into a definitive agreement to acquire Abiomed, Inc. (NasdaqGS:ABMD) for $17.4 billion.

Impella RP Flex with SmartAssist Receives FDA Approval to Treat Right Heart Failure

Abiomed, Inc. Successfully Completes All Impella Post-Approval Studies for High-Risk PCI, Cardiogenic Shock, Post-Cardiotomy Cardiogenic Shock and Right Heart Failure

The United States Food and Drug Administration Grants 510(k) Clearance for Impella Low Profile Sheath

Abiomed's Impella low profile sheath gets FDA clearance

Abiomed, Inc. to Report Q2, 2023 Results on Nov 01, 2022

Price target decreased to US$313

Abiomed: Correction Offers Good Buying Opportunity

Abiomed Announces Two Approvals from the U.S. Food and Drug Administration Related to Clinical Research of Impella Heart Pumps in Acute Myocardial Infarction Cardiogenic Shock Patients

U.S. FDA gives two approvals to Abiomed Impella heart pumps

Abiomed Announces Restore EF Study Shows Heart Function, Symptom Improvements for High-Risk PCI Patients Supported by Impella

First quarter 2023 earnings: EPS exceeds analyst expectations

Abiomed, Inc. (NasdaqGS:ABMD) announces an Equity Buyback for $200 million worth of its shares.

Price target decreased to US$319

Abiomed FQ1 2023 Earnings Preview

Abiomed, Inc. to Report Q1, 2023 Results on Aug 04, 2022

Abiomed, Inc., Annual General Meeting, Aug 10, 2022

Abiomed's Profit Growth Slows On R&D, Sales Hold Strong Despite Shortages

Full year 2022 earnings: EPS exceeds analyst expectations

Abiomed, Inc. to Report Q4, 2022 Results on Apr 28, 2022

Abiomed, Inc. Announces Retirement of David Weber as Senior Vice President, Chief Operating Officer

Independent Director recently sold US$1.2m worth of stock

Senior VP & COO exercised options and sold US$3.1m worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Abiomed, Inc. Revises Revenue Guidance for the Fiscal Year 2022

Consensus forecasts updated

Abiomed's Less Troubled 2020 Justifies Multiple, But Medium-Term Headwinds Mean Capital Risk

Early Feasibility Study Demonstrates Successful Use of Abiomed’s preCARDIA Technology

Abiomed, Inc. Announces Regulators Grants Approvals for Impella Surgical Products

Abiomed, Inc. (NasdaqGS:ABMD) agreed to acquire all the assets and business from Sensera, Inc. for $7.5 million.

Independent Director recently sold US$5.1m worth of stock

Second quarter 2022 earnings released: EPS US$1.25 (vs US$1.38 in 2Q 2021)

Abiomed: Impella Will Continue To Drive Revenue Growth

Independent Director notifies of intention to sell stock

Consensus forecasts updated

Chairman exercised options and sold US$8.0m worth of stock

First quarter 2022 earnings released: EPS US$1.38 (vs US$0.99 in 1Q 2021)

Abiomed: Recovery Mode Has Been Activated - Reiterate Buy Rating

Abiomed’s Receives U.S. Food and Drug Administration Pre-Market Approval as Safe and Effective to Treat Acute Right Heart Failure for Up to 14 Days

Chairman exercised options and sold US$7.6m worth of stock

DSMB recommends Abiomed trial for heart pump in cardiogenic shock continue

Abiomed, Inc. (NasdaqGS:ABMD) acquired Precardia Inc.

Abiomed acquires preCARDIA a company targeting acute heart failure

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Senior VP & COO exercised options and sold US$3.7m worth of stock

Boston Scientific’s new clinical trial can impact Abiomed: Raymond James

Full year 2021 earnings released: EPS US$5.00 (vs US$4.49 in FY 2020)

Abiomed, Inc. Provides Earnings Guidance for the Fiscal Year 2022

Abiomed FQ4 2021 Earnings Preview

Abiomed Appoints of Myron L. Rolle to its Board of Directors

VP & Chief Commercial Officer exercised options and sold US$1.5m worth of stock

Third quarter 2021 earnings released: EPS US$1.37 (vs US$1.53 in 3Q 2020)

Analisi delle retribuzioni degli amministratori delegati

AMMINISTRATORE DELEGATO

Mandato

Compensazione

Gruppo dirigente

Durata media

Età media